

PROVIDER QUICK POINTS

PROVIDER INFORMATION

August 21, 2018

Pharmacy Benefit Update – New Drug-Related Step Therapy (ST) with Quantity Limit (QL) Criteria: Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors

Effective November 1, 2018, Blue Cross and Blue Shield of Minnesota (Blue Cross) will require ST for DPP-4 Inhibitors under the pharmacy benefit plan.

The intent of the DPP-4 Inhibitors ST program is to ensure appropriate selection of patients based on product labeling and/or clinical guidelines and/or clinical studies.

The ST requirement for DPP-4 inhibitors is a patient who is concurrently receiving or has tried and failed insulin or a medication that is or contains metformin or a sulfonylurea. The step edit allows for continuation of therapy with the aforementioned medications when a patient is currently receiving the requested medication.

Please note: Quantity Limits are currently in place with DPP-4 Inhibitors.

As stewards of healthcare expenditures for our subscribers, we are charged with ensuring the highest quality, evidence-based care. One method for doing so is through the ST process. The primary purpose is to ensure that evidence-based care is provided to our subscribers, driving quality, safety, and affordability.

DPP-4 Inhibitor Step Therapy Targeted Drugs (Authorized Generics Only)	Quantity Limit (per 30 days)
alogliptin/ metformin	12.5 mg /500 mg – 60 tablets 12.5 mg/1000 mg – 60 tablets
alogliptin	6.25 mg – 30 tablets 12.5 mg – 30 tablets 25 mg – 30 tablets

Products impacted

This notice applies to the following Minnesota Health Care Programs:

- Blue Advantage Prepaid Medical Assistance Program (PMAP)
- Minnesota Senior Care Plus (MSC+)
- MinnesotaCare (MNCare)

The new Pharmacy ST program will be posted by October 1, 2018 and may be accessed using the Blue Cross provider link at **providers.bluecrossmn.com**.

- Under Tools and Resources, select Medical policy, then acknowledge the Acceptance statement
- Select View All Active Policies
- Select Pharmacy Utilization Management Programs

QP72-18

Distribution: Available on providers.bluecrossmn.com. <https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications>

Continued

CoverMyMeds prior authorization request service

Prescribers can submit ePA drug requests for Blue Cross subscribers who have pharmacy benefits through Blue Cross by either submitting a request through CoverMyMeds's (CMM) free web portal or by sending an electronic NCPDP file to Prime through an integrated Electronic Medical Record (EMR) system during the e-prescribing process.

- To access CMM, go to www.covermymeds.com
- The first time you use the portal to submit a PA, you will need to create a CMM account.
- For help using the CMM site select Support (top of the web page) to view FAQs, CMM physician training webinar offerings, and support options to help you get started.

Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.